Xuetao Shi

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Zhenggang Ren, Jianming Xu, Yuxian Bai et al. · The Lancet Oncology · 2021 · 1.1K citations

Medicine, Oncology, Pharmacology +13

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Visual impairment and blindness caused by retinal diseases: A nationwide register-based study

Chuandi Zhou, S. Li, Luyao Ye et al. · Journal of Global Health · 2023 · 41 citations · Full text

Medicine, Ophthalmology, Optometry +17

Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial

Ying–Hong Shi, Guohong Han, Jian Zhou et al. · ˜The œLancet. Gastroenterology & hepatology · 2025 · 39 citations

Medicine, Oncology, Pharmacology +10

Effect of Concomitant Positive Hepatitis B Surface Antigen on the Risk of Liver Metastasis: A Retrospective Clinical Study of 4033 Consecutive Cases of Newly Diagnosed Colorectal Cancer

Tingting Huo, Jingyu Cao, Yaowen Tian et al. · Clinical Infectious Diseases · 2017 · 24 citations · Full text

Medicine, Oncology, Pathology +17